Vivimed Labs’ Joint Venture (JV) has received its first product approval Ranitidine tablet USP, 150 mg (OTC) and will be launched in the US markets. As per the IRI data, the US OTC market for Ranitidine tablets, which is a generic form of the popular brand is Zantac, is around $200 million.
The product will be manufactured at JV's oral dosage manufacturing facility in Chennai. The product will be launched in the US markets immediately. Ranitidine belongs to a class of drugs known as H2 histamine blockers. It is used to treat peptic ulcers of the stomach and intestines and gastroesophageal reflux and heartburn related to indigestion.
Vivimed Labs is engaged in providing specialty chemicals and pharmaceuticals products. The company offers products for oral care, sun care, skin care, hair care, reversacol photochromic dyes, imaging chemicals and nisarg.
